Receive £2,000 in recognition of the time involved in taking part in this trial

We are conducting a clinical trial in healthy male and female volunteers for a new medicine that could be used to treat people with epilepsy.

You will be paid for your time if you take part in this clinical trial.

Clinical trial summary

We are asking up to 66 healthy male and female participants aged 18 to 55 to participate in different parts of a clinical trial for an investigational medicine, so we can see how safe and tolerated the medicine is, how long the medicine stays in your body and how your body processes the new medicine.

The trial will involve you staying with us for 14 days / 13 nights (see below) at our private medical facility in London Bridge.

During your stay, we will conduct safety assessments and collect blood and urine samples to assess the new medicine.

Register for this clinical trial

If you are interested in participating in the trial:-

  • You will need to attend a screening appointment so we can check if you are suitable to take part in the trial. At this appointment we perform a number of tests including, taking blood, checking your heart, and carrying out a physical examination to see if you will be OK to take part in the clinical trial.
  • If results from your screening appointment show you are suitable for the trial, you will be invited to take part.
  • This will involve a stay of 14 days / 13 nights in our clinical research unit.
  • After your stay with us, you will be required to return for further appointments on Day 21, Day 31, Day 41, and Day 51. This means the whole study takes approximately 12 weeks from your screening visit through to your final visit.
  • In total, if you are included in the clinical trial you will come to the research unit 6 times.
  • During your stay with us you will receive a single dose of the new medicine, once a day, for 11 consecutive days (i.e. Day 1 to Day 11) via your mouth as well as a single dose of the marketed antifungal medicine called Itraconazole on Day 11 via your mouth. We will conduct a number of assessments (like those we did at screening) to check how well you tolerate the new medicine, and to help us understand how long it takes for your body to clear the new medicine from your system.

Register your interest in this clinical trial

Clinical trial dates

Cohort 1

September 2021
MTWTFSS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
October 2021
MTWTFSS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
November 2021
MTWTFSS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
In House Period
Follow Up Appointment

Cohort 2

October 2021
MTWTFSS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
November 2021
MTWTFSS
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
In House Period
Follow Up Appointment
Register your interest in this clinical trial

Who can take part?

We will check your suitability for the clinical trial using the following criteria:-

  • You are a male or female aged between 18 to 55 years inclusive.
  • You must have a bodyweight of 50 to 100 kg and your Body Mass Index (BMI) is between 18.5 and 30.0 kg/m2, inclusive.
  • You must be healthy with no underlying medical conditions that may affect the trial or put you at any significant risk.
  • You must not test positive for alcohol or show any evidence of alcohol abuse.
  • You must not test positive for drugs or show any evidence of drug abuse.
  • You must not use prescription drugs, over-the-counter medication, or supplements within 14 days prior to the investigational medicine administration.
  • Female participants of childbearing potential, if heterosexually active, must agree to the use of highly effective contraception starting from one complete menstrual cycle prior to the first dose until 3 months after your last dose.
  • Male participants must be willing to use appropriate barrier contraception starting from the first day of dosing until 3 months after your last dose, with female partners of child-bearing potential, including partners that are already pregnant.
  • Female participants must not be pregnant or breastfeeding.
  • You must not have used tobacco in any form (e.g. smoking or chewing) or other nicotine-containing products in any form (e.g. gum, patch, and electronic cigarettes) within 60 days prior to the first dose.
  • You must not have had a COVID-19 vaccine 14 days prior to the first dose or plan to receive the vaccine for the entire duration of the study (before the last follow-up visit).
  • You must not donate blood within 30 days prior to study drug administration throughout the study.

A full list of do’s and don’ts will be given to you by a member of our recruitment team if you are interested and want to find out more.

Clinical trial Payment

In recognition of the time involved in taking part in the trial, you will receive £2,000 (£1,333 clinical trial payment and £667 compliance payment) on completion of the clinical trial, provided you comply fully with all the clinical trial requirements. This amount is based on the anticipated clinical trial plan and will be adjusted pro-rata (i.e. same amount of money paid per unit of time), should we invite you to attend extra visits.

Contact our Volunteer Recruitment team

For more information call +44 (0) 20 7042 5800 or email:

volunteer@richmondpharmacology.com

Register your interest in this clinical trial

You may be required to remain resident in the unit until the resolution of any safety issues, after which you will be discharged from the unit.

The contents of this page have been approved by an ethics committee. Any response to this advertisement will be recorded. Your response will not place you under any obligation to participate in this trial.

Ref: C17030_MAR_2021 (email_website_advert text)